Kaisman-Elbaz Tehila, Elbaz Yonatan, Merkin Vladimir, Dym Lianne, Noy Ariel, Atar-Vardi Maya, Bari Romi, Turiel Sivan, Alt Adi, Zamed Tali, Eskira Yael, Lavrenkov Konstantin, Kezerle Yarden, Dyomin Victor, Melamed Israel
Department of Neurosurgery, Soroka University Medical Center, Be'er Sheva, Israel.
Faculty of Health Sciences, Ben-Gurion University of the Negev, Be'er Sheva, Israel.
Front Oncol. 2020 Apr 17;10:432. doi: 10.3389/fonc.2020.00432. eCollection 2020.
Glioblastoma multiforme (GBM) is known for its dismal prognosis, though its dependence on patients' readily available RBCs parameters is not fully established. In this work, 170 GBM patients, diagnosed and treated in Soroka University Medical Center (SUMC) over the last 12 years were retrospectively inspected for their survival dependency on pre-operative RBCs parameters. Besides KPS and tumor resection supplemented by oncological treatment, age under 70 (HR = 0.4, 95% CI 0.24-0.65, = 0.00073), low hemoglobin level (HR = 1.79, 95% CI 1.06-2.99, = 0.031), and Red Cell Distribution Width (RDW) < 14% (HR = 0.57, 95% CI 0.37-0.88, = 0.018) were found to be prognostic of patients' overall survival in multivariate analysis, accounting for a false discovery rate of < 5% due to multiple hypothesis testing. According to these results, a stratification tree was made, from which a favorable route highlighted a subgroup of nearly 30% of the cohorts' patients whose median overall survival was 21.1 months (95% CI 16.2-27.2)-higher than the established chemo-radiation standard first-line treatment regimen overall median survival average of about 15 months. The beneficial or detrimental effect of RBCs parameters on GBM prognosis and its possible causes is discussed.
多形性胶质母细胞瘤(GBM)的预后很差,不过其与患者易于获取的红细胞参数之间的依赖关系尚未完全明确。在本研究中,我们回顾性分析了过去12年在索罗卡大学医学中心(SUMC)诊断并接受治疗的170例GBM患者,以了解术前红细胞参数对其生存的影响。除了KPS评分、肿瘤切除及肿瘤治疗外,多因素分析发现年龄小于70岁(HR = 0.4,95% CI 0.24 - 0.65,P = 0.00073)、低血红蛋白水平(HR = 1.79,95% CI 1.06 - 2.99,P = 0.031)以及红细胞分布宽度(RDW)< 14%(HR = 0.57,95% CI 0.37 - 0.88,P = 0.018)是患者总生存的预后因素,多重假设检验的错误发现率< 5%。根据这些结果,构建了一个分层树,从中一条有利路径突出显示了一组占队列近30%的患者,其总生存中位数为21.1个月(95% CI 16.2 - 27.2),高于既定的化疗 - 放疗一线治疗方案的总生存中位数平均约15个月。本文还讨论了红细胞参数对GBM预后的有益或有害影响及其可能原因。